Xilio Therapeutics, Inc. (NASDAQ:XLO) Major Shareholder Gilead Sciences, Inc. Buys 485,250 Shares of Stock

Xilio Therapeutics, Inc. (NASDAQ:XLOGet Free Report) major shareholder Gilead Sciences, Inc. acquired 485,250 shares of the business’s stock in a transaction dated Tuesday, April 2nd. The stock was purchased at an average price of $0.76 per share, with a total value of $368,790.00. Following the completion of the acquisition, the insider now directly owns 7,345,473 shares in the company, valued at approximately $5,582,559.48. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Major shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.

Xilio Therapeutics Trading Down 12.2 %

XLO opened at $1.30 on Thursday. The stock has a 50-day moving average price of $0.73 and a 200-day moving average price of $1.13. Xilio Therapeutics, Inc. has a 12-month low of $0.49 and a 12-month high of $3.67.

Hedge Funds Weigh In On Xilio Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the company. Citadel Advisors LLC purchased a new position in shares of Xilio Therapeutics in the 4th quarter worth about $28,000. Charles Schwab Investment Management Inc. purchased a new position in shares of Xilio Therapeutics in the 2nd quarter worth about $31,000. Dimensional Fund Advisors LP bought a new stake in shares of Xilio Therapeutics in the 1st quarter valued at about $57,000. Morgan Stanley lifted its stake in shares of Xilio Therapeutics by 274.4% in the 4th quarter. Morgan Stanley now owns 25,611 shares of the company’s stock valued at $69,000 after acquiring an additional 18,771 shares during the last quarter. Finally, Bridgeway Capital Management LLC lifted its stake in shares of Xilio Therapeutics by 40.7% in the 4th quarter. Bridgeway Capital Management LLC now owns 155,481 shares of the company’s stock valued at $86,000 after acquiring an additional 45,000 shares during the last quarter. 54.29% of the stock is currently owned by hedge funds and other institutional investors.

About Xilio Therapeutics

(Get Free Report)

Xilio Therapeutics, Inc, a clinical-stage biotechnology company, discovers and develops tumor-activated immuno-oncology therapies. Its checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 1 clinical trial for patients with advanced solid tumors.

Read More

Receive News & Ratings for Xilio Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xilio Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.